Alysian supported a top-tier PE firm in its acquisition of a pharma-analytics company, with a valuation of over €5 billion, delivering full separation on time, and setting the client up for future transformation and integration success.
Our client is a global leader in pharma-analytics. Following acquisition by PE, Alysian were asked to support the delivery of a successful separation from the seller, managing the IT PMO, Applications, Infrastructure and Data workstreams. The client elected not to use a Prime SI, and delivery was instead split over multiple 3rd Party Suppliers, with Alysian being the primary client partner, providing program orchestration and control.
During the separation planning phase, a new PE bought in, and a ‘shell’ company was established which included the original portfolio company, along with 4 similar companies. This expanded the focus of the program from a pure separation to a combined separation and re-integration with transformation.
At all stages, the team were fully embedded into Client workstreams to seamlessly support Tech & Business facing off to external parties (sell-side, Vendors, 3rd Party Suppliers).
Alysian helped the Client achieve a successful TSA Exit on-time, within budget and on-quality.
Greenfield instances of ERP and CRM were deployed, and end-user facing digital products were migrated to a new AWS.
Overall, 1400 end-users had their M365 accounts and EUC devices migrated, most having legacy devices MTO’d.
Due to Testing diligence, a very low number of Hypercare issues were experienced.
® 2025 Alysian. All Rights Reserved